Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the appointment of Dr. Brian Alvin Johns as the firm’s Chief Scientific Officer (CSO), effective from January 3, 2024. In his new role, Dr. Johns will be responsible for overseeing the company’s discovery programs and charting the future pipeline strategy and priorities for Brii Bio.
Dr. Johns brings a wealth of experience to Brii Bio, having previously served as CSO at HemoShear Therapeutics, Inc., where he led his team to identify novel targets and platforms across a spectrum of disease areas. His earlier tenure included a significant role as vice president of discovery at ViiV Healthcare and GlaxoSmithKline, where he played a pivotal part in ViiV/GSK’s HIV franchise. His contributions were instrumental in the discovery of groundbreaking medications such as dolutegravir and cabotegravir, which have had a significant impact on the field of HIV treatment.- Flcube.com
